Actualités

Strong Wegovy demand lifted revenue as earnings missed estimates

Novo Nordisk stock jumped early Wednesday on a strong first-quarter report on the back of its GLP-1 drugs Wegovy and Ozempic.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 1% and the actively traded

News of the day for May 6, 2026

Find insight on Novo Nordisk, Hartalega, Smith & Nephew and more in the latest Market Talks covering Health Care.

First-quarter sales of the oral Wegovy pill hit $353 million, more than double analyst expectations, as the company lifted its full-year outlook

The main US stock measures were pointing higher in Wednesday's premarket activity, while oil prices

Novo Nordisk (NYSE:NVO) raised its full-year guidance on Wednesday, citing continued strong demand for its obesity and diabetes treatments despite softer underlying first-quarter results caused by pricing pressure. The pharmaceutical group said it now expects adjusted sales and operating profit for 2026 to decline between 4% and 12% at constant exchange rates, representing a narrower contraction than previously anticipated and reflecting stronger expectations for its GLP-1 treatment portfolio.

The launch in January came amid a battle in the market with Mounjaro manufacturer Eli Lilly.

Novo Nordisk stock rose as it raised its guidance on the back of the strong performance of its weight-loss pill.

Shares in Advanced Micro Devices and Intel surge after AMD CEO Lisa Su flags surging demand for central processing units.

Total prescriptions for the new Wegovy pill reached around 1.3 million in the first quarter and have exceeded 2 million since it launched.

↗️Advanced Micro Devices (AMD): Shares of the chipmaker soared premarket after it reported stronger sales and logged higher profit. Shares of its peer Super Micro Computer Inc. (SMCI) also jumped premarket.

Shares in Wegovy maker Novo Nordisk surged this morning after it reported strong demand for its new weight-loss pill and upgraded its guidance. The Danish drugmaker said total prescriptions for the Wegovy pill reached around 1.

May 6 (Reuters) - European shares rose on Tuesday, with oil prices dropping and investor optimism rising after U.S.

Total prescriptions for the Wegovy pill reached around 1.3 million in the first quarter and have exceeded 2 million since it launched.

COPENHAGEN, May 6 () - Novo Nordisk, the maker of weight-loss drug Wegovy, on Wednesday reported first-quarter revenue and adjusted operating profit above expectations and said its outlook ‌for the year was slightly improved. The Danish drugmaker is banking on demand for ‌its new weight-loss pill as competition with U.

VTRS gears up to report Q1 results as import alerts, regional pressures and growth in key brands shape expectations ahead of May 7 release.

Lilly's Foundayo is off to a strong start, drawing new prescribers and patients as broad pharmacy access and payer coverage fuel early oral obesity momentum.

Eli Lilly (NYSE:LLY) received another bullish call from Wall Street. Barclays analyst Emily Field raised her price target on Eli Lilly stock to $1,400 from $1,350 and reiterated an Overweight rating, citing tirzepatide momentum that “takes focus back to the big picture.” The firm also lifted its estimates following the company’s Q1 2026 report. For ... Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show

Competition from Eli Lilly puts pressure on margins despite strong early uptake

Novo Nordisk A/S (NYSE:NVO) is experiencing strong early uptake for its new weight-loss pill, but intensifying competition with U. S.

Novo Nordisk's oral semaglutide for obesity is gaining traction as demand picks up for the new pill version of Ozempic. The FDA has proposed restricting compounding of GLP-1 drugs such as semaglutide, which could support branded products. Rival Eli Lilly is facing delays to its own obesity pill, giving Novo Nordisk more room to build its lead in oral GLP-1 therapies. Novo Nordisk is responding with new leadership, pricing changes, and cost reductions to sharpen its obesity drug focus. Novo...

These stocks have been struggling over the past year, but their growth days are far from over.

NVO heads into Q1 with strong GLP-1 drug demand and new Wegovy pill rollout, but pricing pressure, weak guidance and Eli Lilly rivalry weigh on outlook.

CPRX's Q1 earnings are expected to beat estimates on strong Firdapse demand and rising Agamree sales, while Fycompa faces patent-driven pressure.

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1 2026 earnings release and reflects a model update rather than a wholesale thesis change. Amgen stock recently slipped, trading at $324 as of Monday after closing at ... Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?

The Food and Drug Administration has recorded two ‘serious’ cases in patients taking Eli Lilly’s weight-loss pill.

Investing.com -- Eli Lilly and Company (NYSE:LLY) fell 3% Monday, while Novo Nordisk (NYSE:NVO) rose 2% after Evercore ISI analyst Umer Raffat flagged a liver case in the FDA adverse event database that has "potential to create confusion" for Eli Lilly.

First quarter earnings season is in full swing, with a full slate of semiconductor and consumer companies slated to report results.